reemplazo valvular mitral por cateter en insuficiencia mitral sintomática

Transcatheter Mitral Valve Replacement for Severe Mitral Regurgitation: A Global Study

Symptomatic mitral regurgitation is associated with high morbidity and mortality that can be alleviated partly by surgical mitral valve replacement. However, many patients do not undergo surgery. Transcatheter mitral valve replacement is an appealing option for this selected patient group.   This study aimed to examine the effectiveness and safety of transcatheter mitral valve replacement<a href="https://solaci.org/en/2017/01/27/transcatheter-mitral-valve-replacement-for-severe-mitral-regurgitation-a-global-study/" title="Read more" >...</a>

TAVR vs. Surgery: Valve Performance at Five Years (PARTNER I)

The aim of this study was to evaluate the long-term performance of transcatheter aortic valve replacement (TAVR) and surgically-implanted valves through longitudinal echocardiographic follow-up of the PARTNER I trial patients.   The study included all patients receiving TAVR or undergoing surgery who had a post-implant echocardiogram at five years analyzed for peak systolic velocity, mean gradient,<a href="https://solaci.org/en/2017/01/13/tavr-vs-surgery-valve-performance-at-five-years-partner-i/" title="Read more" >...</a>

Post TAVR Cognitive Function at Short Term: Better or Worse?

There is little information on the short and mid-term evolution of cognitive function after transcatheter aortic valve replacement (TAVR).   The aim of this study was to describe global changes in cognitive function and changes in specific cognitive domains one year after TAVR.   Fifty one patients undergoing TAVR, median age 80, were prospectively followed<a href="https://solaci.org/en/2017/01/11/post-tavr-cognitive-function-at-short-term-better-or-worse/" title="Read more" >...</a>

Momento de la estrategia invasiva luego de un infarto sin supradesnivel del ST

Post NSTEMI Invasive Strategy Timing

The aim of this meta-analysis, which included all randomized studies carried out to date, was to compare an early invasive strategy vs. a delayed invasive strategy in patients undergoing non ST elevation myocardial infarction (NSTEMI).   Even though there is no doubt invasive strategies reduce events rate such as death and re-infarction in NSTEMI patients,<a href="https://solaci.org/en/2016/12/19/post-nstemi-invasive-strategy-timing/" title="Read more" >...</a>

Carotid Revascularization After Stroke: When Should It Be Performed?

In 2006, the American Heart Association guidelines recommended that carotid revascularization be performed within 2 weeks of stroke based on data from 2 randomized trials on carotid endarterectomy.   This study aimed to determine whether the time between the event and revascularization has decreased after these guidelines were issued, and the proportion of patients receiving some sort of revascularization (endarterectomy<a href="https://solaci.org/en/2016/12/19/carotid-revascularization-after-stroke-when-should-it-be-performed/" title="Read more" >...</a>

troponina t ultrasensible valor pronóstico

Post PCI High Sensitivity Troponin Elevation: No Prognostic Value

The prognostic value of high sensitivity troponin elevation after elective PCI in patients with or without elevated baseline values remains unclear.   The aim of this study was to measure the prognostic value of post elective procedure high sensitivity troponin and to determine whether this may be influenced by baselines TnT values.   The study<a href="https://solaci.org/en/2016/12/13/post-pci-high-sensitivity-troponin-elevation-no-prognostic-value/" title="Read more" >...</a>

TAVR in Pure Aortic Insufficiency: Yes or No?

Courtesy of Dr. Agustín Vecchia. Surgery is the treatment of choice for patients with symptomatic aortic insufficiency and/or ventricular dilatation or decreased ventricular function. The broad implementation of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, the emergence of new devices, and the experience acquired by operators have brought this treatment to off-label indications such<a href="https://solaci.org/en/2016/12/13/tavr-in-pure-aortic-insufficiency-yes-or-no/" title="Read more" >...</a>

Contemporary Ventricular Assist Devices: Hemodynamic Consequences

Courtesy of Dr. Agustín Vecchia. Despite current technological advancements and improvement in reperfusion rates in a setting of infarction, cardiogenic shock still is a relatively frequent complication with a mortality rate close to 50%. The need to augment cardiac output in these patients and the fact that the popular intraaortic balloon counterpulsation has not been able to<a href="https://solaci.org/en/2016/11/25/contemporary-ventricular-assist-devices-hemodynamic-consequences/" title="Read more" >...</a>

TAVR: The Need for a Pacemaker Is Associated with Mortality

Courtesy of Dr. Carlos Fava.   After a transcatheter aortic valve replacement (TAVR), the incidence of permanent pacemaker (PPM) implantation ranges from 6% to 30% in different studies, depending on the valve type used. This is due to trauma, ischemia, haemorrhage, and atrioventricular node and infranodal tissue oedema, provoking ventricular dyssynchrony similar to that caused by<a href="https://solaci.org/en/2016/11/18/tavr-the-need-for-a-pacemaker-is-associated-with-mortality/" title="Read more" >...</a>

Valve Thrombosis After TAVR: Larger-Diameter Valves and No Warfarin as Predictors

There are limited data on the incidence, clinical implications, and predisposing factors of valve thrombosis in patients who underwent transcatheter aortic valve replacement (TAVR). This study aimed at determining such information through multislice computed tomography (CT).   This trial included 460 consecutive patients who underwent TAVR with a balloon-expandable Edwards Sapien XT or Sapien 3 (Edwards Lifesciences,<a href="https://solaci.org/en/2016/11/13/valve-thrombosis-after-tavr-larger-diameter-valves-and-no-warfarin-as-predictors/" title="Read more" >...</a>

left main